Aktis Oncology (NASDAQ:AKTS) Stock Rating Upgraded by BMO Capital Markets

Aktis Oncology (NASDAQ:AKTS) was upgraded by analysts at BMO Capital Markets to a “strong-buy” rating in a research note issued to investors on Tuesday, Marketbeat.com reports.

AKTS has been the subject of several other research reports. Weiss Ratings upgraded Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. HC Wainwright upped their target price on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Wall Street Zen cut Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Raymond James Financial began coverage on Aktis Oncology in a research note on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their price target on Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Aktis Oncology has an average rating of “Buy” and a consensus price target of $35.00.

Aktis Oncology Trading Up 0.1%

Shares of AKTS opened at $25.02 on Tuesday. The stock has a market capitalization of $1.34 billion and a price-to-earnings ratio of -30.51. Aktis Oncology has a 12 month low of $14.72 and a 12 month high of $34.19. The firm has a fifty day simple moving average of $25.35 and a 200 day simple moving average of $21.25.

Aktis Oncology (NASDAQ:AKTS) last issued its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The business had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $2.70 million. As a group, research analysts predict that Aktis Oncology will post -1.76 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Ken Herrmann sold 4,856 shares of the firm’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $24.56, for a total value of $119,263.36. Following the completion of the sale, the director directly owned 3,506 shares in the company, valued at approximately $86,107.36. This trade represents a 58.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 3.30% of the company’s stock.

Institutional Trading of Aktis Oncology

A number of hedge funds have recently made changes to their positions in the business. Bank of America Corp DE boosted its stake in shares of Aktis Oncology by 4.2% during the 2nd quarter. Bank of America Corp DE now owns 72,835 shares of the technology company’s stock worth $2,347,000 after acquiring an additional 2,909 shares during the period. Bank of New York Mellon Corp raised its stake in Aktis Oncology by 14.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 49,250 shares of the technology company’s stock valued at $1,587,000 after acquiring an additional 6,349 shares during the period. The Manufacturers Life Insurance Company raised its stake in Aktis Oncology by 2.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,044 shares of the technology company’s stock valued at $1,548,000 after acquiring an additional 1,051 shares during the period. Wellington Management Group LLP acquired a new stake in Aktis Oncology during the 2nd quarter valued at $63,372,000. Finally, Deutsche Bank AG boosted its position in Aktis Oncology by 49.3% during the second quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock worth $678,000 after purchasing an additional 6,942 shares during the period. 28.84% of the stock is owned by institutional investors and hedge funds.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.